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Lafora progressive myoclonus epilepsy (LD) is a fatal autosomal recessive neurodegenerative disorder
characterized by the presence of glycogen-like intracellular inclusions called Lafora bodies. LD is caused
by mutations in two genes, EPM2A and EPM2B, encoding respectively laforin, a dual-speciﬁcity protein phos-
phatase, and malin, an E3 ubiquitin ligase. Previously, we and others have suggested that the interactions
between laforin and PTG (a regulatory subunit of type 1 protein phosphatase) and between laforin and
malin are critical in the pathogenesis of LD. Here, we show that the laforin–malin complex downregulates
PTG-induced glycogen synthesis in FTO2B hepatoma cells through a mechanism involving ubiquitination
and degradation of PTG. Furthermore, we demonstrate that the interaction between laforin and malin is a
regulated process that is modulated by the AMP-activated protein kinase (AMPK). These ﬁndings provide
further insights into the critical role of the laforin–malin complex in the control of glycogen metabolism
and unravel a novel link between the energy sensor AMPK and glycogen metabolism. These data advance
our understanding of the functional role of laforin and malin, which hopefully will facilitate the development
of appropriate LD therapies.
INTRODUCTION
Lafora progressive myoclonus epilepsy (LD, OMIM 254780) is
an autosomal recessive neurodegenerative disorder character-
ized by the presence of glycogen-like intracellular inclusions
named Lafora bodies (1–5). LD is a fatal disorder that occurs
worldwide, but is relatively more frequent in Mediterranean
countries. LD initially manifests during adolescence with gen-
eralized tonic-clonic seizures, myoclonus, absences, drop
attacks or visual hallucinations. As the disease proceeds, a
rapidly progressive dementia with apraxia, aphasia and visual
loss ensues, leading patients to a vegetative state and death,
usually within the ﬁrst decade from onset of the ﬁrst symptoms
(6,7). Mutations have been identiﬁed in two genes, EPM2A
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Advance Access published on November 20, 2007(8,9) and EPM2B (10), although there is evidence for a third
locus (11). EPM2A, located on chromosome 6q24 (12,13), is
mutated in 60% of LD cases. EPM2A encodes laforin, a
dual-speciﬁcity protein phosphatase of 331 amino acids
with a functional carbohydrate binding domain at the N-
terminus (14,15). Several proteins have been recently reported
to interact with laforin (7): (i) a protein of unknown function
named EPM2AIP1; (ii) HIRIP5, a cytosolic protein with
a housekeeping function that may be involved in iron
homeostasis (16); (iii) GSK3b, a crucial component of both,
the Akt/PKB kinase and the Wnt signaling pathways (17,18)
and (iv) R5/PTG (19), one of the glycogen-targeting regulatory
subunits of type 1 protein phosphatase (PP1), which favors the
assembly of PP1 with its substrates, glycogen synthase (GS),
phosphorylase (Ph) and phosphorylase kinase (PhK), and
enhances glycogen accumulation (20–22). Laforin thus
appears tobepartofamultiproteincomplex thatmaybeassoci-
ated with the formation of intracellular glycogen particles. In
fact, using multiple mouse models, it has been recently
described that the levels of laforin protein closely correlate
with the levels of intracellular glycogen. This observation
suggests a direct relationship between laforin and glycogen
levels (23). In addition, it has been described that laforin is
able to form homodimers (19,24), which is critical for the phos-
phatase activity of laforin. Laforin has also been implicated in
the Wnt signaling pathway, as it has been reported to dephos-
phorylate GSK3b (24). However, multiple reports have since
demonstrated by several methods that GSK3b is not a substrate
of laforin (25,26). Thus, the physiological relevance of the
interaction between laforin and GSK3b is controversial.
A second gene, EPM2B, located on chromosome 6p22.3,
was recently found to be mutated in 20–30% of LD patients
(10,27). EPM2B encodes malin, an E3 ubiquitin ligase of
395 amino acids with a RING ﬁnger domain at the N-terminus
and six NHL domains in the C-terminal region (10,17,28). It
has been recently described that malin interacts with and ubi-
quitinates laforin, leading to its degradation (28).
Both the formation of laforin–malin complexes and the
observation that patients with mutations in laforin or malin
are neurologically and histologically indistinguishable
(27,29), strongly suggest that the two LD proteins operate
through common physiological pathways.
In this report, we show that the laforin–malin complex
downregulates PTG-induced glycogen synthesis in FTO2B
hepatoma cells through a mechanism involving ubiquitination
and degradation of PTG, similar to that recently described in
neuronal cells (30). Most importantly, we show that the for-
mation of the laforin–malin complex is a regulated process
and that AMP-activated protein kinase (AMPK) plays a criti-
cal role in this regulation. The involvement of AMPK in the
regulation of the laforin–malin complex adds a metabolic
component to our understanding of the pathogenesis of LD.
RESULTS
Impaired formation of laforin–malin–PTG complexes
is critical in the pathogenesis of LD
Yeast two-hybrid analysis and pull-down assays demonstrated
that laforin interacted physically with malin, in agreement
with recent reports (17,28). Moreover, the laforin binding site
was located within the four C-terminal NHL domains of
malin (residues 208–395) (data not shown). Similarly, func-
tional analysis of several laforin and malin mutations identiﬁed
in patients with LD indicated that the formation of the laforin–
malin complex and its interaction with PTG is crucial in LD
pathogenesis (Supplementary Material, Fig. S1). Since laforin
forms stable complexes with malin and also interacts with
PTG, we tested whether malin also interacted with PTG.
Although, we could not detect a direct interaction between
malin and PTG, a robust two-hybrid interaction between PTG
and malin was observed when laforin was overexpressed in
these assays (Fig. 1). These results suggest the formation of a
possible ternary complex in which laforin would tether the
interaction between malin and PTG. Similar results were
obtained with laforin C266S, an artiﬁcial laforin mutant that
interacts properly with malin, but lacks phosphatase activity
(Supplementary Material, Fig. S1), indicating that the for-
mation of ternary complexes between laforin, malin and PTG
did not require the phosphatase activity of laforin (Fig. 1).
The laforin–malin complex prevents glycogen
accumulation caused by overexpression of PTG
in FTO2B hepatoma cells, ubiquitinates PTG and targets
it for degradation
Recently, we described a novel mechanism for the regulation of
glycogen synthesis that involves the laforin–malin complex in
neurons. This regulatory mechanism controls the levels of GS
and PTG via a proteasomal degradation pathway (30). Because
disturbance of this novel glycogen regulatory mechanism, as a
consequence of mutations in laforin or malin, may explain the
generation of the glycogen-like intracellular inclusions (Lafora
bodies) present in all tissues of LD patients, we determined
whether this glycogen regulatory mechanism also operates in
tissues that normally synthesize glycogen, such as liver. Using
FTO2B hepatoma cells as a model system, we observed that
treatment of these cells with increasing amounts of adenovirus
expressing a GFP–PTG fusion protein (Ad–GFP–PTG)
resulted in a dose-dependent enhancement of glycogen accumu-
lation (Fig. 2A). The PTG-induced glycogen accumulation was,
however, progressively prevented by the co-infection of FTO2B
cells with increasing amounts of adenovirus expressing laforin
(Ad–laforin) and malin (Ad–malin) (Fig. 2B). This effect was
dependent on the presence of both laforin and malin, since in
the absence of one of them, no inhibition of the glycogenic pro-
perties of PTG was observed (Fig. 2B). The co-expression of
laforin and malin with GFP–PTG in FTO2B cells resulted in a
drastic reduction in the levels of GFP–PTG (Fig. 2C). The
levels of laforin were also diminished, in agreement with a
recent report indicating that malin interacts with and ubiquiti-
nates laforin, leading to its degradation (28). However, the
co-expression of laforin and malin did not change the total
levels of GS in FTO2B cells. This result is consistent with the
observation that only the muscular GS isoform (MGS), but not
the liver isoform (LGS), is degraded by the overexpression of
laforin and malin in neuron cells (30) and unpublished data),
suggesting the existence of tissue-speciﬁc differences in the
regulation of glycogen synthesis by the laforin–malin
complex. We also found that the levels of accumulated glycogen
668 Human Molecular Genetics, 2008, Vol. 17, No. 5correlated directly with the activity of GS. We observed an
increase in the GS activity ratio (2Glu-6P/þGlu-6P) when the
cells were infected with Ad–GFP–PTG adenovirus (ratio of
0.46versus0.13,observedincellsinfectedwithAd–GFPadeno-
virus) and a decrease in the GS activity ratio when the cells were
co-infected with Ad–GFP–PTG, Ad–laforin and Ad–malin
(ratio of 0.34). Consistent with these results, we observed a
partial recovery of the phosphorylated status of GS at Ser461
when the cells were co-infected with Ad–GFP–PTG, Ad–
laforin and Ad–malin adenovirus (a sign of GS inactivation).
These results indicated an inhibition of the dephosphorylating
activity of PTG under the later conditions, possibly as a conse-
quence of lower levels of this protein (Fig. 2C).
To determine whether the reduction in the levels of PTG was
due to an increased ubiquitin-dependent proteasomal degra-
dation, mediated by the laforin–malin complex, we expressed
in HEK293 cells a myc-tagged form of PTG (myc-PTG) and
a modiﬁed form of ubiquitin (tagged with 6xHis residues),
which allowed the puriﬁcation of ubiquitin-tagged proteins by
metal afﬁnity chromatography (TALON column; see Materials
and Methods). As observed in Figure 3, in the bound fraction of
the TALON column, the anti-myc antibody detected a poly-
dispersed high molecular weight material (lanes 2 and 3),
which was absent in the cells that expressed myc-PTG, but
not the modiﬁed form of ubiquitin (lane 1), indicating that
myc-PTG was ubiquitinated in vivo (Ub-myc-PTG). Interest-
ingly, the co-expression of laforin and malin improved the ubi-
quitination of myc-PTG (lane 3) in comparison with cells that
only co-expressed malin (lane 2) or with cells that did not
co-express laforin and malin (data not shown). No high molecu-
lar weight forms of myc-PTG were observed in the crude
extracts, possibly due to the low abundance of these forms
due to their rapid degradation. These results suggest that the
laforin–malin complex modiﬁed PTG and targeted it for
ubiquitin-dependent proteasomal degradation. The afﬁnity
column also retained unspeciﬁcally the unmodiﬁed form of
myc-PTG, perhaps due to the polysaccharide binding domain
Figure 1. Laforin tethers the interaction between PTG and malin. Yeast
CTY10-5d strain was transformed with plasmids pEG202-PTG (LexA.PTG),
pACT2-malin (GAd–malin) or pACT2 (GAD, empty plasmid) and plasmids
pSK93 (empty), pSK-laforin or pSK-laforin C266S. Transformants were
grown until exponential phase (A600 0.5) in selective SC medium containing
4% glucose. Protein interaction was estimated using the yeast two-hybrid
system, by measuring the b-galactosidase activity. Values correspond to
means from 4 to 6 different transformants (bars indicate standard deviation),
  P , 0.01.
Figure 2. Laforin–malin complex counteracts the glycogenic effect of PTG.
(A) Rat hepatoma FTO2B cells were infected with increasing amounts of
Ad–GFP–PTG adenovirus or with 30 ml of Ad–GFP adenovirus. Twenty-
four hours after the infection, the amount of glycogen was determined as
described in Materials and Methods. Bars indicate standard deviation of
three independent experiments (  P , 0.01;    P , 0.001). (B) FTO2B
cells were infected with 300 ml of Ad–GFP–PTG and increasing amounts
of Ad–laforin and Ad–malin adenovirus. Twenty-four hours after the infec-
tion, the amount of glycogen was determined as described in Materials and
Methods. Bars indicate standard deviation of at least three independent experi-
ments (    P , 0.001). (C) Cell extracts (60 mg) from FTO2B cells treated as
in section (B) were obtained and analyzed by western blotting using anti-GFP,
anti-GS, anti-phospho Ser461 GS, anti-actin, anti-laforin or anti-HA anti-
bodies (Ad–malin adenovirus produces an N-terminal HA-tagged malin).
Human Molecular Genetics, 2008, Vol. 17, No. 5 669present in PTG that reacted with the polysaccharide base of the
TALON column (Fig. 3, asterisk).
The laforin–malin interaction is modulated
by the AMP-activated protein kinase
Since laforin and malin formed a functional complex (dis-
cussed earlier), we studied next how the formation of this
complex could be regulated. Two-hybrid analysis of yeast
cells co-transformed with laforin and malin demonstrated a
three-fold increase of the laforin–malin interaction when the
cells were incubated in low (0.05%) glucose containing
medium (Fig. 4A). These conditions in yeast determine acti-
vation of the Snf1 kinase, the orthologue of the human cataly-
tic subunit of the AMPK, a metabolic-sensing protein that
plays a key role in maintaining the cellular energy balance
(31). AMPK is a serine/threonine protein kinase that acts as
a sensor of the cellular energy status. Once activated, it
switches on catabolic pathways and switches off many ATP-
consuming processes including anabolic pathways [see (32–
35), for review]. Activation of AMPK requires phosphoryl-
ation of the a catalytic subunit by an upstream kinase, with
LKB1 and CaMKKb sharing this role (36–39).
To test whether the Snf1 kinase modulated the interaction
between laforin and malin, we used a yeast mutant lacking
the Snf1 kinase (snf1D) and observed that the interaction
between laforin and malin did not increase in the presence of
low (0.05%) glucose conditions (Fig. 4B). Concurrently, trans-
formation of wild-type yeast cells with a constitutively acti-
vated form of the catalytic subunit of mammalian AMPK
[KD T172D; (40,41)] increased the interaction between
laforin and malin in high (4%) glucose conditions, to levels
comparabletothoseobservedinlow(0.05%)glucose(Fig.4C).
In contrast to other eukaryotes, yeast accumulates glycogen
when growing under low glucose conditions. To demonstrate
that the increase in the interaction between laforin and malin
was due to the action of Snf1/AMPK proteins and not to the
accumulation of glycogen, we measured the interaction in a
gac1D yeast mutant, lacking the main regulatory subunit of
the PP1 (yeast PTG orthologue), that targets the phosphatase
catalytic subunit to substrates involved in glycogen metabolism.
This mutant is unable to accumulate glycogen, whereas the
Snf1 pathway is still activated upon growth in low glucose con-
ditions (42). As shown in Figure 4B, the interaction between
laforin and malin increased in the gac1D mutant when
growing in low (0.05%) glucose conditions, as observed in
the wild-type control. In addition, we did not observe any
accumulation of glycogen in cells growing in high (4%)
glucose and expressing the plasmid pSK-KDT172D (data not
shown). These data suggested that the increase in the interaction
between laforin and malin was related to the action of Snf1/
AMPK proteins and not to the accumulation of glycogen in
yeast cells. This modulation seems speciﬁc for the interaction
between laforin and malin since AMPK activation did not
affect the interaction between laforin and PTG (data not
shown).
AMPK interacts and phosphorylates laforin in vitro
AMPK is a heterotrimer comprised of a catalytic subunit (a), a
scaffolding subunit (b) also involved in substrate recognition,
and a regulatory subunit (g). To characterize the potential
interaction between laforin and/or malin and AMPK, we per-
formed a yeast two-hybrid analysis with the a2, b2 and g1
AMPK subunits, the most abundant isoforms found in liver
and skeletal muscle. These analyses showed that laforin inter-
acted with the catalytic AMPKa2 and the AMPKb2 scaffold-
ing subunits, but not with AMPKg1 (Fig. 5A). These
interactions were not regulated by the level of glucose (data
not shown). In contrast to laforin, malin did not interact with
any of the AMPK subunits (Fig. 5A) (an empty LexA
plasmid in combination with the three AMPK subunits gave
less than 1 Unit of b-galactosidase activity; data not shown).
We conﬁrmed that laforin interacted with AMPK in vivo by
co-immunoprecipitation experiments using HEK293 cells
transfected with pCINeo::laforin and pCMV-HA-AMPKa2.
As shown in Figure 5B, cell extracts immunoprecipitated
using an anti-HA monoclonal antibody (to immunoprecipitate
AMPKa2) co-immunoprecipitated laforin. We next analyzed
whether puriﬁed AMPK could phosphorylate GST::laforin in
vitro. These in vitro experiments, in addition to further corro-
borating the interaction between laforin and AMPK, demon-
strated that AMPK was able to phosphorylate recombinant
GST::laforin produced in bacteria (Fig. 5C). Taken together,
these data suggest that AMPK might be involved in the regu-
lation of the laforin–malin complex.
A dominant negative form of AMPK impairs the effect
of the laforin–malin complex on the glycogenic
activity of PTG
Following our observations that the laforin–malin complex
downregulates the glycogenic activity of PTG and that the
Figure 3. PTG is ubiquitinated in vivo. HEK293 cells were transfected with
pCMV-myc-PTG and with the indicated combinations of pCMV-Ubiqx6His,
pcDNA3-HA-malin and pCINeo::laforin plasmids. Thirty-six hours after
transfection, cells were broken in lysis buffer containing guanidinium–HCl
(see Materials and Methods) and 4 mg of protein of clariﬁed extracts were
loaded on a TALON column. The column was extensively washed and
ﬁnally eluted with 2x Laemmli sample buffer. Hundred microgram of clariﬁed
extracts and the eluted fraction from the TALON column were analyzed by
immunoblotting using anti-myc antibodies. The unmodiﬁed myc-PTG
protein is retained unspeciﬁcally in the TALON column (asterisk).
670 Human Molecular Genetics, 2008, Vol. 17, No. 5Figure 4. AMPK regulates the interaction between laforin and malin. (A) The laforin–malin interaction is enhanced by low glucose. Yeast CTY10-5d strain was
transformed with plasmids pEG202-laforin (LexA-laforin) and pACT2-malin (GAD–malin) or the empty plasmid pACT2 (GAD). Transformants were grown
until exponential phase (A600 0.5) in selective SC medium containing 4% glucose, and then washed with water and transferred to a 0.05% glucose medium for
3 h. Protein interaction was estimated using the yeast two-hybrid system, by measuring the b-galactosidase activity. Values correspond to means from 4 to 6
different transformants (bars indicate standard deviation),    P , 0.001. (B) Yeast FY250 wild-type, gac1D and snf1D mutant strains containing the reporter
plasmid pSH18-18 (6lexAop-lacZ) were transformed with plasmids pEG202-laforin and pACT2-malin. Transformants were grown until exponential phase
(A600 0.5) in selective SC medium containing 4% glucose, and then washed with water and transferred to a 0.05% glucose medium for 3 h. Protein interaction
was estimated using the yeast two-hybrid system, by measuring the b-galactosidase activity. Values represent means of 4 to 6 different transformants (bars indi-
cate standard deviation),    P , 0.001. (C) Yeast CTY10-5d strain containing plasmids pEG202-laforin and pACT2-malin was transformed with plasmids
pSK93 (empty) or pSK-KDT172D, expressing a constitutively active form of AMPKa2 subunit. Transformants were grown until exponential phase (A600
0.5) in selective SC medium containing 4% glucose. Protein interaction was estimated using the yeast two-hybrid system, by measuring the b-galactosidase
activity. Values represent means of 4 to 6 different transformants (bars indicate standard deviation),    P , 0.001.
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we postulated that the disruption of the endogenous laforin–
malin complex by expressing a dominant negative form of
the catalytic subunit of AMPK (a1-D157A; DN-AMPK)
should result in an enhancement in the glycogenic activity
of PTG. In agreement with this idea co-infection of FTO2B
cells with Ad–GFP–PTG and Ad–DN-AMPK adenovirus
resulted in a statistically signiﬁcant enhancement of the glyco-
genic activity of PTG (Fig. 6A). Co-infection of Ad–
DN-AMPK with an adenovirus expressing only GFP (Ad–
GFP) did not increase glycogen accumulation, indicating
that DN-AMPK by itself did not have glycogenic activity.
We also analyzed the effect of AMPK activation. Treatment
of Ad–GFP–PTG infected cells with AICAR (0.5 mM,6 h ,
to activate endogenous AMPK) did not change the amount
of accumulated glycogen in comparison with untreated Ad–
GFP–PTG infected cells (Fig. 6A).
We tested next whether DN-AMPK could prevent the
downregulation of the glycogenic activity of PTG induced
by the overexpression of laforin–malin complex. FTO2B
cells co-infected with Ad–GFP–PTG, Ad–DN-AMPK,
Ad–laforin and Ad–malin adenovirus showed a statistically
signiﬁcant increase in the glycogenic activity of PTG
(Fig. 6B), as compared to the cells that were not infected
with Ad–DN-AMPK, suggesting that the DN-AMPK pre-
vented the downregulatory action of the laforin–malin
complex, likely by interfering with the laforin–malin inter-
action. In this sense, western blot analysis indicated a partial
recovery of the levels of GFP–PTG in the cells co-infected
with the four adenovirus (Fig. 6C). Interestingly, the levels
of laforin were also higher in this case (Fig. 6C), perhaps as
a consequence of the impairment of the interaction between
laforin and malin.
We suggested above that the increase in the glycogenic
properties of PTG produced by the co-infection with Ad–
DN-AMPK (Fig. 6A) was due to the disruption of the
endogenous laforin–malin complex. If our hypothesis was
correct, elimination of laforin or malin from the cells should
prevent the DN-AMPK-mediated enhancement of the glyco-
genic activity of PTG. To address this point, we used two
primary ﬁbroblasts cell lines derived from LD patients carry-
ing the laforin mutations Y86X and R241X, respectively,
and cell lines from healthy control ﬁbroblasts. These ﬁbro-
blasts were infected with Ad–GFP–PTG and/or Ad–
DN-AMPK adenovirus. Figure 7A illustrates an enhanced
accumulation of glycogen in all ﬁbroblast cell lines when
they were infected with Ad–GFP–PTG, which was higher
in LD-derived ﬁbroblasts. However, in contrast to healthy
control ﬁbroblasts, the co-infection with Ad–DN-AMPK of
LD-derived ﬁbroblasts did not enhance the glycogenic activity
of PTG. These results suggest that in the absence of functional
laforin–malin complex (either because one of the components
is missing or because the formation of the functional complex
is prevented), the glycogenic activity of PTG is at maximum.
DISCUSSION
LD is caused by mutations in the EPM2A or EPM2B genes,
encoding laforin or malin, respectively. Although the roles
of these two proteins in cellular physiology are still poorly
understood, several reports have provide evidence suggesting
that the disruption of protein–protein interactions involving
laforin and malin are critical for the pathogenesis of LD.
One of the histological determinants characteristic of LD is
the accumulation of glycogen-like intracellular inclusions
named Lafora bodies. Glycogen metabolism is mainly regu-
lated by the phosphorylation of the proteins involved in glyco-
gen synthesis (glycogen synthase, GS) and degradation
(glycogen phosphorylase, Ph and glycogen phosphorylase
kinase, PhK) (43,44). Interestingly, while there are several
kinases (AMPK, PKA, CKI, GSK3, etc.) that inhibit glycogen
Figure 5. AMPK interacts with and phosphorylates laforin. (A) Yeast
CTY10-5d strain was transformed with plasmids pACT2-AMPKa2,
pACT2-AMPKb2, pACT2-AMPKg1 or pACT2 (empty; GAD) and
pEG202-laforin (LexA-laforin) or pEG202-malin (LexA-malin). Cells were
grown until exponential phase (A600 0.5) in selective SC medium containing
4% glucose. Protein interaction was estimated using the yeast two-hybrid
system, by measuring the b-galactosidase activity. Values represent means
of 4 to 6 different transformants (bars indicate standard deviation),    P ,
0.001. (B) Laforin co-immunoprecipitates with AMPKa2. HEK293 cells
were transfected with pCINeo::laforin and pCMV-HA-AMPKa2 (HA-a2).
Complexes between AMPKa2 and laforin were immunoprecipitated from
lysates using an anti-HA monoclonal antibody. Western blots of immunopre-
cipitates were probed with an anti-laforin monoclonal antibody. Cell extracts
and IP in the absence of antibody (Ø) are included as controls. (C) GST::la-
forin (300 ng) and GST (100 ng), produced in bacteria and afﬁnity puriﬁed
using GSH-agarose, were phosphorylated in vitro using 50 mUnits of
AMPK (Upstate) and [g-
32P]ATP, following the manufacturer’s instructions.
Samples were analyzed by SDS–PAGE and autoradiography. Size standards
are indicated in kDa.
672 Human Molecular Genetics, 2008, Vol. 17, No. 5Figure 6. DN-AMPK prevents the effect of the laforin–malin complex on PTG. (A) Rat hepatoma FTO2B cells were infected with Ad–GFP–PTG (300 ml) or
Ad–GFP (30 ml) and Ad–DN-AMPK (300 ml). Twenty-four hours after the infection, an aliquot of Ad–GFP–PTG infected cells was treated with AICAR
(0.5 mM, 6 h) and the amount of glycogen in all the samples was determined as described in Materials and Methods. Bars indicate standard deviation of ﬁve
independent experiments;    P , 0.001). (B) FTO2B cells were infected with Ad–GFP–PTG (300 ml) and also with either Ad–GFP (30 ml), a combination
of Ad–laforin and Ad–malin (100 ml each) or a combination of Ad–laforin, Ad–malin (100 ml each) and Ad–DN-AMPK (300 ml). Twenty-four hours
after the infection, the amount of glycogen was determined as described in Materials and Methods. Bars indicate standard deviation of ﬁve independent experi-
ments;    P , 0.001. (C) Cell extracts (60 mg) from FTO2B cells treated as in section (B) were obtained and analyzed by western blotting using anti-GFP,
anti-laforin, anti-HA (Ad–malin adenovirus produces an N-terminal HA-tagged malin), anti-AMPKa anti-GS or anti-actin antibodies.
Human Molecular Genetics, 2008, Vol. 17, No. 5 673synthesis by the phosphorylation of GS, there is only one
known phosphatase, PP1, that induces glycogen synthesis by
activating GS and inactivating the glycogen degradation
enzymes Ph and PhK (43,44). PP1 is recruited to glycogen
by a family of glycogen targeting proteins including GM,
GL, PTG and R6 (43–45), whose overexpression results in
glycogen accumulation (20,45). In this study, we present evi-
dence for the critical role of the interaction between laforin,
malin and PTG in LD pathogenesis.
We show here that laforin and malin play a crucial role in
the regulation of glycogen biosynthesis in FTO2B hepatoma
cells. In these cells, the laforin–malin complex counteracts
the glycogenic effect of PTG because it promotes its ubiquiti-
nation and degradation. It has been described that in this type
of cells PTG preferentially affects Ph and PhK over GS (46–
48). Therefore, the laforin–malin dependent inactivation of
PTG may ensure that Ph and PhK remain phosphorylated
(active), which would prevent glycogen accumulation
(Fig. 8). This mechanism is analogous to the one recently
described in neurons (30). However, in neuronal cells, where
no Ph and PhK are present but GS is clearly expressed
(30,49), the role of the laforin–malin complex may be critical
to maintain glycogen synthesis silenced in a cell that does not
have the ability to degrade glycogen. LD patients lacking a
functional laforin–malin complex would be unable to regulate
PTG and GS, leading to glycogen accumulation in neurons
(Fig. 8). Consistent with this interpretation, an LD patient
with mutations in laforin shows a dramatic increase in the
total levels of GS in skeletal muscle compared to a control
individual (SRdeC, unpublished data). Further studies would
be needed to reconcile these data with early studies in LD
patients (50) and studies in mouse models (25,51) reporting
that the activity of the enzymes involved in glycogen meta-
bolism is not markedly affected.
Since the role of the laforin–malin complex is critical, we
hypothesized that the formation of the laforin–malin
complex must be also tightly regulated. Here, we provide evi-
dence indicating that the formation of the laforin–malin
complex is positively regulated by AMPK. We show that
laforin, but not malin, can interact physically with the catalytic
subunit of AMPK and that puriﬁed AMPK phosphorylates
GST::laforin in vitro. Moreover, we demonstrate that the
addition of a dominant negative form of the catalytic subunit
of AMPK (DN-AMPK) prevents the function of the laforin–
malin complex on the glycogenic activity of PTG, probably
by interfering with the interaction between laforin and
malin. As a result of this interference, malin is no longer
able to access its substrates, laforin and PTG, thus the degra-
dation of these two proteins is prevented.
These data provide evidence for an additional function of
AMPK in glycogen metabolism, where its activation is
known to lead to an increase in the phosphorylation and inac-
tivation of GS and also to an increase in glucose uptake (52–
54). However, in FTO2B hepatoma cells, the contribution of
these two mechanisms to the overall regulation of glycogen
accumulation seems to be fairly low since treatment of these
cells with AICAR (an AMPK activator) did not promote gly-
cogen accumulation and treatment of Ad–GFP–PTG-infected
cells with AICAR did not change the amount of glycogen
accumulated in comparison with untreated Ad–GFP–
PTG-infected cells. These results suggest that in these cells,
the regulation of the function of PTG is key to adjust glycogen
accumulation. A diagram depicting our hypothesis with the
potential roles of the laforin–malin complex, its relationship
with other proteins in glycogen metabolism and the differ-
ences between the mechanism operating in neurons and
FTO2B hepatoma cells is provided in Figure 8.
Figure 8. Proposed role for the laforin–malin complex, PTG and AMPK in
glycogen biosynthesis. See text for details. PP1c, catalytic subunit of type 1
protein phosphatase; LGS, liver glycogen synthase isoform; MGS, muscle gly-
cogen synthase isoform; Ph: glycogen phosphorylase.
Figure 7. The effect of DN-AMPK on the glycogenic activity of PTG requires
the presence of laforin. (A) Primary ﬁbroblasts from a healthy control and
from LD-patients with the laforin mutations Y86X and R241X were infected
with low dose (30 ml) of Ad–GFP or Ad–GFP–PTG adenovirus in combi-
nation with or without Ad–DN-AMPK (300 ml). Twenty-four hours after
the infection, the amount of glycogen was determined as described in
Materials and Methods. The increase in the glycogen content with respect to
the treatment with Ad–GFP is plotted. Bars indicate standard deviation of
three independent experiments. Only in healthy control ﬁbroblasts, a statisti-
cally signiﬁcant difference in the levels of glycogen of cells treated with
Ad–GFP–PTG in combination or not with Ad–DN-AMPK was observed
( P , 0.05,   P , 0.01,    P , 0.001). (B) Crude extracts (60 mg) from
cells treated as in section (A) were obtained and analyzed by western blotting
using anti-GFP and anti-AMPKa antibodies. The position of an anti-GFP
cross-reacting band is indicated with an asterisk.
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homeostasis has been described (26). In this case, laforin
acts as a phosphatase of complex carbohydrates (i.e. amylo-
pectin) and it has been proposed that this function might be
necessary for the maintenance of normal cellular glycogen.
In addition to PTG, malin and AMPK, laforin has been
shown to interact with other proteins (16–19,55), suggesting
that there are other regulatory roles for the laforin–malin
complex besides glycogen metabolism. This is an important
issue because it is currently unknown whether lafora bodies
have a causative relationship with the epilepsy and neurode-
generation, or whether these LD features are independent con-
sequences that result from the disturbance of a common
physiological pathway. In this sense, it has been recently
described that defects in protein degradation and clearance
are likely to be the primary trigger in the pathophysiology
of LD (56). Further elucidation of the mechanisms by which
the formation of the laforin–malin complexes is regulated
and of the mechanisms by which these complexes regulate
PTG and glycogen synthesis in general, should lead to signiﬁ-
cant advances in the understanding of the pathogenesis of LD
and hopefully, to the development of therapies.
MATERIALS AND METHODS
Recombinant plasmids
pGBT9-laforin and pACT2-laforin plasmids have been
described previously (19). Plasmids pEG202-laforin and
pGEX6P1-laforin were obtained by subcloning a BamHI/
SalI fragment from pGBT9-laforin into pEG202 (Clontech)
and pGEX6P1 (Amersham Biosciences), respectively. Malin
was ampliﬁed from human genomic DNA by PCR and
cloned into the prokaryote vector pGEX-A (Invitrogen). The
ﬁnal construct, pGST::malin, encoded a recombinant malin
protein with GST fused at its N-terminus. Malin cDNA was
also cloned into pcDNA3-HA (Invitrogen) and the yeast
vectors pEG202 and pACT2 (Clontech). Laforin and malin
containing plasmids were also used as templates for the intro-
duction of EPM2A and EPM2B missense and non-sense
mutations by PCR, using the QuickChange Site-Directed
Mutagenesis Kit (Stratagene) and appropriate mutagenic oli-
gonucleotides. All expression constructs were fully sequenced
to exclude the presence of undesired mutations resulting from
PCR ampliﬁcation. A pCINeo::laforin plasmid was used to
express laforin in COS7 or HEK293 cells. A constitutively
active form of the kinase domain of a2 catalytic subunit of
AMPK (KDT172D) was constructed as in Scott et al. (40).
The fragment was subcloned into plasmid pSK93 (57) to
obtain plasmid pSK-KDT172D (58). Wild-type laforin and
C266S mutant cDNAs were also subcloned into plasmid
pSK93 to obtain plasmids pSK-laforin and pSK-laforin
C266S. Plasmids pACT2-AMPKa2, pACT2-AMPKb2,
pACT2-AMPKg1 and pCMV-HA-AMPKa2 are described in
(58).
Yeast two-hybrid analyses
Yeast CTY10.5d strain was co-transformed with pACT2-laforin
and different pEG202-malin plasmids (wild-type and mutants).
b-Galactosidase activity was assayed in permeabilized cells and
expressed in Miller Units as in (59). For the yeast two-hybrid
analyses using pGBT9-laforin (wild-type and mutants) as bait,
yeast strain AH109 (Clontech) was co-transformed with
pACT2-malin plasmid. Transformants were analyzed as in (19).
Expression of recombinant proteins in Escherichia coli
EscherichiacolitransformantsharboringdifferentGST-fusions
were grown in 500 ml of LB/ampicillin. Transformants were
grown at 378C until the absorbance at 600 nm reached a
value of around 0.3. IPTG (isopropyl-b-D-thiogalactoside)
was then added to a concentration of 0.1 mM, and cultures
were maintained overnight at 258C. Cells were harvested and
resuspended in 20 ml of sonication buffer [50 mM HEPES-
NaOH pH 7.0, 150 mM NaCl, 10% glycerol, 0.1% Triton
X-100, 2 mM DTT, 2 mM PMSF and complete protease inhibi-
tor cocktail (Roche)]. Cells were disrupted by sonication and
the fusion proteins puriﬁed by passing the extracts through
1 mlbedvolumeofglutathione-sepharosecolumns(Amersham
Biosciences).GST-fusionproteinswereelutedfromthecolumn
with 25 mM glutathione. Samples were stored at 2808C.
Co-immunoprecipitation and GST pull-down analyses
Immunoprecipitationswereperformedusingtransfectedhuman
embryonic kidney HEK293 cells. To identify laforin–
AMPKa2 complexes, subconﬂuent cultures of HEK293 cells
growing in Dulbecco’s modiﬁed Eagle’s medium (DMEM;
Invitrogen) supplemented with 10% inactivated fetal bovine
serum (FBS, GIBCO) plus 100 units/ml penicillin, 100 mg/ml
streptomycin and 2 mM glutamine, were co-transfected with
3 mg of pCINeo-laforin and 3 mg of pCMV-HA-AMPKa2,
using the calcium phosphate protocol. Transfected cells were
scraped in lysis buffer [50 mM Tris–HCl pH 7.5; 10 mM
NaCl, 50 mM EDTA; 15% glycerol, 1% nonidet P-40
(NP-40), complete protease inhibitor cocktail (Roche), 1 mM
PMSF, 50 mM NaF and 5 mM Na2P2O7]. Cells were lysed by
successive rounds of freeze and thawing. Cell lysates were
then centrifuged at 13,000  g for 15 min at 48C. Laforin–
AMPKa2complexes wereimmunoprecipitated fromthe super-
natants (500 mg of total protein) with anti-HA monoclonal anti-
body. Western blots of the immunoprecipitates were probed
withamonoclonal anti-laforin antibodyandasheepanti-mouse
IgG conjugated to HRP. The HRP signal was detected by using
the ECL plus western blotting detection system (Amersham
Biosciences).
Immunoblotting
Sixty microgram of total protein from the soluble fraction of
cell lysates prepared as above were analyzed by SDS–
PAGE and western blotting using appropriate antibodies:
rabbit polyclonal anti-GFP (Molecular Probes), rabbit polyclo-
nal anti-GS (60), rabbit polyclonal anti-phospho Ser461 GS
(Cell signaling), mouse monoclonal anti-laforin (19), rabbit
polyclonal anti-LexA (Invitrogen), mouse monoclonal
anti-HA (Sigma), rabbit polyclonal anti-actin (Sigma) and
rabbit polyclonal anti-AMPK (Cell Signaling).
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Ubiquitination assays were carried outby mixing puriﬁedGST-
recombinant proteins (full length malin; malin-C26S and
malin-D146 N), mammalian E1 (5 ng/ml; Biomol), one type
of mammalian E2 [UbcH7 or UbcH5a, or inactive [C
85A]
UbcH5a (25 ng/ml, Afﬁnity)] and ubiquitin (100 ng/ml;
Sigma), in ubiquitination buffer (250 mM Tris–HCl pH 7.4,
12.5 mM MgCl2, 2.5 mM DTT and 10 mM ATP). Samples
were incubated at 258C for 1.5 h and reactions were stopped
by boiling the mixtures in SDS–PAGE sample buffer for
10 min. Proteins were separated by SDS–PAGE and visualized
by immunoblotting using anti-GST (Santa Cruz Biotechnol-
ogy) and anti-ubiquitin (FK2, Biomol) monoclonal antibodies.
Analysis of in vivo ubiquitination of PTG
To study the in vivo ubiquitination of PTG, HEK293 cells
were transfected with pCMV-myc-R5 and combinations of
pCMV-Ubiqx6His (encoding a modiﬁed ubiquitin, tagged
with six His residues; a gift from Dr M. Rodriguez, Proteomics
Unit, CIC-BioGUNE, Vizcaya), pcDNA3-HA-malin or pCI-
Neo::laforin plasmids, using the Fugene HD reagent (Roche)
according tothemanufacturer ´sinstructions.After 36 hoftrans-
fection, cells were lysed in buffer A (6 M guanidinium–HCl,
0.1 M sodium phosphate, 0.1 M Tris–HCl, pH 8.0). Four milli-
gram of protein of a clariﬁed extract (12 000 g, 15 min) was
incubated with a 100 ml of a TALON column (Clontech) in
the presence of 10 mM imidazole, for 3 h at room temperature
on a rocking platform, to purify His-tagged proteins. The
column was then successively washed with 2 ml each of
buffer B (buffer A plus 10 mM imidazole), buffer C (buffer B,
but with 8 M urea instead of 6 M guanidinium–HCl) and
four more times with buffer C adjusted to pH 6.0. Bound pro-
teins were eluted with 50 ml2   Laemmli’s sample buffer
and analyzed by western-blotting with an anti-myc monoclonal
antibody (Sigma).
AMPK in vitro phosphorylation assay
Fifty nanogram of puriﬁed GST-fusion proteins were phos-
phorylated with 50 mU of AMPK (Upstate), in a ﬁnal
volume of 20 ml of a buffer containing 20 mM HEPES-NaOH
pH 7.0, 1 mM dithiothreitol, 10 mM MgCl2, 300 mM AMP and
100 mM of a mixture of g-
32P-ATP (3000 Ci/mmol) and cold
ATP, following the manufacturer’s instructions (Upstate). The
reaction was incubated at 308C for 1 h and stopped by boiling
the mixtures in sample buffer. Samples were analyzed by
SDS–PAGE and autoradiography. Two hundred and ﬁfty
nanogram of GST-fusion proteins were analyzed by SDS–
PAGE and stained with Coomassie blue.
Adenovirus infection
Rat hepatoma FTO2B cells were cultured in complete Dulbec-
co’s Modiﬁed Eagle’s medium (DMEM, Invitrogen) sup-
plemented with 10% inactivated fetal bovine serum (FBS,
GIBCO), 100 units/ml penicillin, 100 mg/ml streptomycin
and 2 mM glutamine. Cells of number 10
6 were plated
onto 60 mm-diameter culture dishes the day before infection.
Infection with the corresponding adenovirus was carried out
in 1 ml of complete DMEM containing 0.5% FBS. The follow-
ing adenovirus were used in this work: Ad–GFP (10
11 pfu/ml),
Ad–GFP–PTG (2x10
11 pfu/ml), Ad–laforin (2x10
12 pfu/ml)
and Ad–malin (4x10
12 pfu/ml) (30), and Ad–DN-AMPK
(10
11 pfu/ml; kindly supplied by Dr Pascal Ferre ´, INSERM
Unit 671, Universite Paris 6, Centre de Recherches Biomedi-
cales des Cordeliers, Paris, France). Two hours after infection,
adenovirus-containing medium was replaced with fresh
complete DMEM containing 0.5% FBS. Twenty-four hours
after infection, cells were washed with PBS and frozen in
liquid N2 until analysis.
Primary ﬁbroblasts from the skin of two LD patients, carry-
ing the Y86X and R241X laforin mutations, were cultured
using standard procedures and were routinely transformed
using a plasmid (T22) containing the SV40 T antigen (kindly
supplied by Dr M. Ugarte, Universidad Auto ´noma de Madrid,
Spain). GM03349 ﬁbroblasts from human skin (Coriell Cell
Repositories, USA) were used as healthy controls. Fibroblasts
were cultured in complete DMEM supplemented with
15% inactivated FBS. 150 000 cells were plated onto
60 mm-diameter culture dishes for 3 days. Fibroblasts were
then infected with the corresponding adenoviruses as above.
Glycogen and GS activity determination
To measure glycogen content, cell monolayers were scraped
into 30% KOH and the extract was then heated at 1008Cf o r
15 min. Glycogen was then measured as described previously
(61). The amount of glycogen is expressed as the amount of
released glucose per mg of total protein. GS activity was
measured in cell homogenates in the absence or presence of
6.6 mM Glu-6P, as described previously (62). The 2Glu-6P/þ
Glu6P activity ratio is a non-linear measurement of the acti-
vation state of the enzyme. Values below 0.1 indicate an
essentially fully inactive enzyme, whereas values above 0.7
are equivalent to full activation (63).
Statistical data analysis
Data are expressed as means+standard deviation. Statistical
signiﬁcance of differences between the groups was evaluated
by a paired Student’s t-test with two-tailed distribution. The
signiﬁcance has been considered at  P,0.05,   P,0.01 and
   P,0.001, as indicated in each case.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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